| Antithrombotic Usage Indications in Atrial Fibrillation | Ahmet AKYOL | 1–6 |
| Physician Responsibilty and Medical Malpractice After the Legal Regulations | Gürcan ALTUN, Abdullah Coşkun YORULMAZ | 7–12 |
| Coronary Artery Disease Management in Polyclinic | , Elçim DURUSOY, Tarık YILDIRIM, Armağan ALTUN | 13–18 |
| The Follow-Up of Diabetic Patient in Polyclinic | Betül Uğur ALTUN | 19–25 |
| Vasodilatator Beta Blockers in Cardiovascular Disease | Bülent MUTLU | 26–30 |
| How Important is Anemia for the Clinician? | Burhan TURGUT | 31–34 |
| Is Thrombolytic Therapy Effective in Elderly Patients? Bleeding? | Elena TANEVA | 35–38 |
| Follow-up of Patients with Hyperlipidemia in Policlinic | Ersan TATLI | 39–41 |
| Microalbuminuria: a Cardiovascular Risk Factor | Ertuğrul ERCAN | 42–48 |
| Drug-Induced QT Interval Prolongation and Torsade De Pointes: Identification of Risk Factors | Konstantinos P. LETSAS | 49–53 |
| Exercise and Quality of Life | Kyriakos A. PAPAVASİLİOU | 54–56 |
| Follow-up and Treatment of Patients with Heart Failure in Policlinic | Meryem AKTOZ | 57–62 |
| Quality of Life After Stroke | Murat BİRTANE, Nurettin TAŞTEKİN | 63–68 |
| Antithrombotic and Anticoagulant Usage Policies | Muzaffer DEMİR, Emre TEKGÜNDÜZ | 69–73 |
| Syncope: View of Neurologist | S. Naz YENİ | 74–78 |
| What Do We Know About Negative Statin Trials? | Okan ERDOĞAN | 79–81 |
| Direct Inhibition of Renin | Yağız ÜRESİN, Zeynep Güneş ÖZÜNAL |